Clinical Trial Update: Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating safety and tolerability of combining low-dose cytarabine or azacitidine with venetoclax and quizartinib in newly diagnosed acute my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Low-dose cytarabine (Cytarabine (low-dose))
• Quizartinib (Quizartinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Leukemia, Myeloid, Acute, De Novo | Phase 1, Phase 2 | Status: UNKNOWN